Paxlovid
nirmatrelvir / ritonavir
Table of contents
Overview
Paxlovid is a medicine used for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.
Paxlovid contains two active substances, PF-07321332 and ritonavir, in two different tablets.
-
List item
Paxlovid : EPAR - Medicine overview (PDF/128.98 KB)
First published: 28/01/2022
Last updated: 07/03/2023
EMA/38027/2022 -
-
List item
Paxlovid : EPAR - Risk-management-plan (PDF/4.18 MB) (updated)
First published: 27/01/2022
Last updated: 21/09/2023
Authorisation details
Product details | |
---|---|
Name |
Paxlovid
|
Agency product number |
EMEA/H/C/005973
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Therapeutic area (MeSH) |
COVID-19 virus infection
|
Anatomical therapeutic chemical (ATC) code |
J05AE30
|
Publication details | |
---|---|
Marketing-authorisation holder |
Pfizer Europe MA EEIG
|
Revision |
13
|
Date of issue of marketing authorisation valid throughout the European Union |
28/01/2022
|
Contact address |
Boulevard de la Plaine 17 |
Product information
20/07/2023 Paxlovid - EMEA/H/C/005973 - II/0042
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Paxlovid is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID 19.